A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT03357952 · COMPLETED

Trial details

NCT number

NCT03357952

Sponsor

Janssen Research & Development, LLC

Status

COMPLETED

Phase

Phase 2, Phase 3

Study type

INTERVENTIONAL

Start date

2017-11-16

Primary completion

2018-10-24

Enrollment

10

View on ClinicalTrials.gov